GW433908

DRUG4 trials

Sponsors

Glaxo Wellcome, GlaxoSmithKline, ViiV Healthcare

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 2

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

CompletedNCT00071760

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2003-10-23End: 2022-03-29Updated: 2023-10-10

Phase 3

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

Glaxo WellcomeHIV Infections

Start: 2000-11-30Target: 210Updated: 2005-06-24

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Glaxo WellcomeHIV Infections

Start: 2000-11-30Target: 624Updated: 2005-06-24

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

GlaxoSmithKlineHIV Infections

Start: 2001-05-31Target: 330Updated: 2005-06-24